A Study on Safety & Efficacy in Patients With Soft Tissue Sarcomas

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT03985722` - Olaratumab Plus Trabectedin in Advanced Soft-tissue Sarcoma Patients Soft-tissue Sarcoma Patients	Phase 1
Withdrawn	`NCT02464332` - Safety Study of BLZ-100 in Adult Subjects With Sarcoma Undergoing Surgery	Phase 1
Completed	`NCT00289809` - TLC D-99 and Ifosfamide in Metastatic Soft Tissue Sarcoma Patients	Phase 1/Phase 2
Completed	`NCT00243685` - Chemotherapy Drug Sensitivity Microculture (MiCK) Assay for Apoptosis	Phase 2/Phase 3
Active, not recruiting	`NCT01185964` - A Study of IMC-3G3 in Soft Tissue Sarcoma	Phase 1/Phase 2
Completed	`NCT00753688` - Pazopanib Versus Placebo in Patients With Soft Tissue Sarcoma Whose Disease Has Progressed During or Following Prior Therapy	Phase 3
Completed	`NCT00093080` - Study of AP23573/MK-8669 (Ridaforolimus), A Mammalian Target of Rapamycin (mTOR) Inhibitor, in Participants With Advanced Sarcoma (MK-8669-018 AM1)(COMPLETED)	Phase 2
Completed	`NCT00187174` - Everolimus for Treating Pediatric Patients With Recurrent or Refractory Tumors	Phase 1
Completed	`NCT03798795` - Radiomics for Tumor Grading of Soft Tissue Sarcomas.
Terminated	`NCT02929394` - Trabectedin Maintenance Post 1st-line in STS	Phase 3
Recruiting	`NCT02275286` - Trabectedin Plus Radiotherapy in Soft Tissue Sarcoma Patients	Phase 1/Phase 2
Completed	`NCT00406601` - BAY-43-9006 in Advanced, Metastatic Soft Tissue Sarcomas	Phase 2
Completed	`NCT00297258` - Pazopanib In Patients With Relapsed Or Refractory Soft Tissue Sarcoma	Phase 2
Active, not recruiting	`NCT06114173` - Efficacy and Safety Study of Cardunilizumab in Soft Tissue Sarcoma	Early Phase 1
Completed	`NCT00061659` - Study Evaluating the Safety and Efficacy of ABT-510 in Subjects With Locally Advanced or Metastatic Soft Tissue Sarcoma	Phase 2
Recruiting	`NCT03815474` - Anlotinib Hydrochloride Combined With Epirubicin and Ifosfamide for Soft Tissue Sarcoma Patients	Phase 2
Recruiting	`NCT02812654` - Ifosfamide, Doxorubicin and Hypofractionated Radiotherapy in Neoadjuvant Sarcoma Treatment	Phase 2
Completed	`NCT00204620` - Bendamustin Hydrochloride in Patients With Soft Tissue Sarcoma (STS)	Phase 2
Active, not recruiting	`NCT02415816` - Diffusion Weighted Magnetic Resonance in Imaging Younger Patients With Newly Diagnosed Bone or Soft Tissue Sarcomas	N/A
Withdrawn	`NCT02367651` - Study of Pazopanib Versus Placebo as Maintenance Therapy for Advanced Soft Tissue Sarcoma	Phase 2

NCT number	NCT03058406
Study type	Observational
Source	Eisai Inc.
Contact
Status	Completed
Phase
Start date	March 1, 2016
Completion date	November 4, 2018

A Study on Safety and Efficacy in Patients With Soft Tissue Sarcomas — HAL03T

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms